Avadel Pharmaceuticals plc - ADR

NASDAQ:AVDL  
8.12
-0.40 (-4.70%)
Earnings Announcements

Avadel Pharmaceuticals Provides Corporate Update And Reports Third Quarter 2021 Financial Results

Published: 11/08/2021 14:11 GMT
Avadel Pharmaceuticals plc - ADR (AVDL) - Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results.
Q3 Loss per Share $0.38.
FDA Review of NDA for Ft218 Ongoing; Commercial and Launch Preparations Progressing.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.41

Next Quarter Revenue Guidance is expected to be $0.75 Million
Next Quarter EPS Guidance is expected to be -$0.44

More details on our Analysts Page.